Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 1:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–21 of 21 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 5 mg Psilocybin Clear all

Conditions: Binge Eating Disorder
Interventions: TRYP-0082, Psychotherapy; Drug · Behavioral
Lead sponsor: TRYP Therapeutics; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Tobacco Use Disorder
Interventions: Psilocybin, Niacin; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years and older
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 3
States / cities: Birmingham, Alabama • Baltimore, Maryland • New York, New York

Conditions: PTSD
Interventions: Psilocybin 15mg, Psilocybin 25mg; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 21 Years to 64 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Anorexia Nervosa
Interventions: Psilocybin; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Alcohol Use Disorder
Interventions: Psilocybin, Inactive Placebo, Supportive therapy sessions; Drug · Other · Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 65 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: New York, New York

Conditions: Demoralization
Interventions: Psilocybin, Placebo; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 25 Years to 65 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Depressive Symptoms, Depression, Alzheimer Disease, Mild Cognitive Impairment
Interventions: Psilocybin; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Chronic Low Back Pain (CLBP), Physical Therapy, Psilocybin
Interventions: Psilocybin 10 mg, Psilocybin 25 mg, Niacin 100 mg; Drug
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Psilocybin, Music Intervention
Interventions: Psilocybin (high dose), Playlist 1, Playlist 2, Playlist 3, Playlist 4, Playlist 5; Drug · Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cluster Headache
Interventions: 0.143 mg/kg Psilocybin or 10 mg Psilocybin, 0.0143 mg/kg Psilocybin or 1 mg Psilocybin, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Bipolar II Disorder, Depression, Bipolar, Suicidality
Interventions: Psilocybin, Therapeutic Support; Drug · Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 25 Years to 70 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Anorexia Nervosa
Interventions: Psilocybin; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 40 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Depressive Disorder, Major
Interventions: Psilocybin 25 mg, Inactive Placebo, Psilocybin 5 mg, Psychosocial Support; Drug · Behavioral
Lead sponsor: Usona Institute; Other
Eligibility: 18 Years and older
Enrollment: 238 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 29
States / cities: Birmingham, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 25 more

Conditions: Transdiagnostic, Depression - Major Depressive Disorder, Anxiety, PTSD Symptoms, PTSD, Substance Use, Substance Use Disorder (SUD), OCD
Interventions: Psilocybin; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Amblyopia
Interventions: Amblyopia Therapy, 1 mg Psilocybin, 5 mg Psilocybin, 10 mg Psilocybin, 15 mg Psilocybin, 20 mg Psilocybin, 25 mg Psilocybin; Behavioral · Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Anhedonia in Healthy Volunteers, Older Adults (50-90 Years)
Interventions: Psilocybin (drug), Dextromethorphan (DXM); Drug
Lead sponsor: Jennifer Mitchell; Other
Eligibility: 50 Years to 85 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Early-stage Breast Cancer, Fear of Cancer Recurrence, Anxiety, Depression
Interventions: Psilocybin 25 mg, Psilocybin 5 mg; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 21 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2031
U.S. locations: 2
States / cities: Aurora, Colorado • New York, New York

Conditions: Methamphetamine Use Disorder, Human Immunodeficiency Virus (HIV)
Interventions: Psilocybin 5 mg, Psilocybin 25 mg, Motivational Support; Drug · Behavioral
Lead sponsor: Nicky Mehtani, MD, MPH; Other
Eligibility: 25 Years to 64 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Nicotine Dependence
Interventions: Psilocybin-assisted treatment, Nicotine Replacement Therapy (NRT); Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2023
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Cocaine Use Disorder
Interventions: Psilocybin; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 21 Years to 55 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2029
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Major Depressive Disorder
Interventions: Psilocybin; Drug
Lead sponsor: Maryland Oncology Hematology, PA; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Rockville, Maryland

Search by objective public record fields.

Evaluation of Psilocybin (TRP-8802) in the Treatment of Binge Eating Disorder

5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder

State-Funded Trial Assessing Recovery and Long-Term Impact of Guided Psilocybin for Healing Trauma

Effects of Psilocybin in Anorexia Nervosa

Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for AUD

Exploratory Study of Low Dose Psilocybin

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

Psilocybin-Assisted Physical Therapy in Chronic Low Back Pain

PRoMiSS: Psilocybin and the Role of Music in Set and Setting

Psilocybin for the Treatment of Cluster Headache

Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality

Evaluation of Psilocybin in Anorexia Nervosa: Safety and Efficacy

Psilocybin for Major Depressive Disorder (MDD)

Open-Label Psilocybin Study in Transdiagnostic Population

Psilocybin for Amblyopia - Targeting Critical Periods in Humans

A Study of Psychedelics in Healthy Older Adults With Low Well-being

Psilocybin FCR Early-Stage Breast Cancer

Psilocybin Therapy for Methamphetamine Use Disorder and HIV

Psilocybin-facilitated Smoking Cessation Treatment: A Pilot Study

Safety Profile of Psilocybin for Cocaine Use Disorder

The Safety and Efficacy of Psilocybin in Cancer Patients With Major Depressive Disorder